Interestingly, our present study also showed that chemo- and/or immunotherapy of MM, despite the well-known risk of the development of refractoriness [43], is capable of reinforcing both PD-1 and CTLA-4 checkpoint expression, and this notion is consistent with other studies [6,12,44]. This evidence concerns the gene CTLA4 and Miyoshi myopathy.